PI-RADS 5且PSA密度>0.15者可省略系统穿刺
研究纳入112例PI-RADS 5病灶行靶向穿刺和12针系统穿刺的患者,评估系统穿刺对前列腺癌及临床显著前列腺癌(GG≥2)的额外检出价值。PSA密度>0.15 ng/ml²的78例中,省略系统穿刺仅漏检4%临床显著前列腺癌,不影响患者管理,可考虑省略。
要点
- PI-RADS 5且PSA密度>0.15 ng/ml²者,省略系统穿刺仅漏检4%临床显著癌。
- 系统穿刺在靶向穿刺基础上仅额外增加2%前列腺癌和4%临床显著癌检出。
- PSA密度越高,系统穿刺和靶向穿刺的临床显著癌检出率越高。
核心结论
- PI-RADS 5且PSA密度>0.15 ng/ml²患者中,系统穿刺仅轻微增加临床显著前列腺癌检出,不影响管理,可省略。
研究设计与样本
- 前瞻性维护前列腺穿刺数据库中的连续患者,纳入112例mpMRI PI-RADS 5病灶行靶向穿刺加12针系统穿刺者。
主要发现
- 总体队列系统穿刺、靶向穿刺、联合穿刺的前列腺癌检出率分别为89%、93%、95%,临床显著癌分别为72%、81%、85%。
- 系统穿刺在靶向穿刺基础上额外增加2%前列腺癌和4%临床显著癌检出。
- PSA密度>0.15 ng/ml²的78例中,系统穿刺、靶向穿刺、联合穿刺的前列腺癌检出率分别为92%、97%、97%,临床显著癌分别为79%、91%、95%。
- 该人群省略系统穿刺将漏检0例前列腺癌和4%(3例)临床显著前列腺癌。
- 临床显著癌检出率随PSA密度升高而提高:系统穿刺p=0.01,靶向穿刺p<0.0001,联合穿刺p=0.002。
关键数值与推荐
- PI-RADS 5且PSA密度>0.15 ng/ml²时,系统穿刺可省略。
临床怎么用
- 对PI-RADS 5且PSA密度>0.15 ng/ml²的患者,可仅行靶向穿刺而省略系统穿刺,以减少穿刺针数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the prostate cancer and clinically significant prostate cancer detection on systematic biopsy (SB), target biopsy (TB) alone and combined SB and TB in men with Prostate Imaging Reporting and Data System™ (PI-RADS™) 5 lesion. MATERIALS AND METHODS: From a prospectively maintained prostate biopsy database, we identified consecutive patients with PI-RADS 5 lesion on multiparametric magnetic resonance imaging. The patients underwent multiparametric magnetic resonance imaging followed by transrectal TB of PI-RADS 5 lesion and 12-core SB. The prostate cancer and clinically significant prostate cancer (Grade Group, GG ≥2) detection on SB, TB and SB+TB were determined for all men and accordingly to prostate specific antigen density. Statistic significant was set a p <0.05. RESULTS: Overall, 112 patients met inclusion criteria. The detection rate of prostate cancer for SB, TB and SB+TB was 89%, 93% and 95%, respectively, and for clinically significant prostate cancer it was 72%, 81% and 85%, respectively. SB added 2% prostate cancer and 4% clinically significant prostate cancer detection to TB. A total of 78 patients had prostate specific antigen density >0.15 ng/ml2, and the detection rate of PCa for SB, TB and SB+TB was 92%, 97% and 97%, respectively, and for clinically significant prostate cancer it was 79%, 91% and 95%, respectively. In this population, if SB was omitted, 0 prostate cancer and only 4% (3) of clinically significant prostate cancer would be missed. The clinically significant prostate cancer detection rate improved with increased prostate specific antigen density for SB (p=0.01), TB (p <0.0001) and combined SB+TB (p=0.002). CONCLUSIONS: In patients with PI-RADS 5 on multiparametric magnetic resonance imaging and prostate specific antigen density >0.15 ng/ml2, SB marginally increases clinically significant prostate cancer detection, but not overall prostate cancer detection in comparison to TB alone. Systematic biopsy did not affect patients' management and can be omitted on this population.
引用
- Tafuri A, Iwata A, Shakir A, et al. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15. J Urol. 2021. PMID: 33818141. doi:10.1097/JU.0000000000001766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。